
Citizens raised the firm’s price target on Iovance (IOVA) to $12 from $8 and keeps an Outperform rating on the shares. Iovance reported Q3 results and highlighted a robust clinical
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IOVA | Iovance Biotherapeutics | 7.76 | 5.29 | 214.17% |
| Name | Price | % Change | |
|---|---|---|---|
| $7.76 | +214.17% |

Citizens raised the firm’s price target on Iovance (IOVA) to $12 from $8 and keeps an Outperform rating on the shares. Iovance reported Q3 results and highlighted a robust clinical

Barclays raised the firm’s price target on Iovance (IOVA) to $19 from $18 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for

Iovance Biotherapeutics (($IOVA)) has held its Q3 earnings call. Read on for the main highlights of the call. Iovance’s earnings call carried a strongly positive tone, driven by record revenue,

The latest update is out from Iovance Biotherapeutics ( ($IOVA) ). On November 5, 2026, Iovance Biotherapeutics updated its corporate presentation for healthcare conferences, analysts, stockholders and other audiences. The

Reports Q3 revenue $121.47M, consensus $115.57M. “Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand,” said Frederick

The company said, “Improvements in gross margin are expected to continue, excluding occasional one-time items.” Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

UBS raised the firm’s price target on Iovance (IOVA) to $8 from $7 and keeps a Neutral rating on the shares ahead of its Q3 results. The firm notes the

Analyst David Dai of UBS maintained a Hold rating on Iovance Biotherapeutics, boosting the price target to $8.00. David Dai’s rating is based on a balance between Iovance Biotherapeutics’ commercial

Baird lowered the firm’s price target on Iovance (IOVA) to $9 from $11 and keeps a Neutral rating on the shares. The firm updated its model following its NSCLC data

Iovance Biotherapeutics ( ($IOVA) ) has issued an announcement. On October 29, 2026, Iovance reported updated Phase 2 IOV-LUN-202 data in previously treated non-squamous metastatic non-small-cell lung cancer showing a
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| hold | Assigned | Nov 3, 2026 | ||||
| hold | Reiterated | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 23, 2026 | ||||
| buy | Reiterated | Sep 29, 2026 | ||||
| buy | Initiated | Sep 24, 2026 | ||||
| buy | Reiterated | Aug 17, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 2, 2027TBA | $3.59B | $-0.04 | $128.58M | 0.17 | -14.64 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.